検索結果

ound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

iod required for regulatory approval, resulting in early approval and launch. CRAO, the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

announce today that it has been applied for manufacturing and marketing approval in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...